SMU-14a

• Description:

  SMU-14a is a TLR3 inhibitor (IC50: 0.18 µM) . SMU-14a inhibits IL-6 secretion in mouse peritoneal macrophages and downregulates TNF-α in human peripheral blood monocytes. SMU-14a exerts anti-inflammatory effects by reducing the phosphorylation of p65, ERK, and TBK1 through NF-κB, MAPK, and IRF3 signaling pathways, and decreasing serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. SMU-14a can be used in the study of acute hepatitis[1].

• UNSPSC:

  12352005

• Target:

  ERK; IKK; NF-κB; p38 MAPK; TNF Receptor; Toll-like Receptor (TLR)

• Related Pathways:

  Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; NF-κB; Stem Cell/Wnt

• Field of Research:

  Inflammation/Immunology

• Smiles:

  O=C(C1=CC2=C(NC3=C2C(C)=C(C=NC=C4)C4=C3C)C=C1)NC5=CC=CC=C5N

• Molecular Formula:

  C24H20N4O

• Molecular Weight:

  380.44

• References & Citations:

  [1]Cao Z, et al. Ellipticine derivatives as Toll-like receptor 3 inhibitor for treating acute hepatitis. Eur J Med Chem. 2025 Sep 15;294:117762.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported